PRTK

Paratek Pharmaceuticals Inc

Healthcare


Presented:05/11/2018
Price:$11.40
Cap:$0.35B
Current Price:$2.23
Cap:$0.13B

Presented

Date05/11/2018
Price$11.40
Market Cap$0.35B
Ent Value$0.27B
P/E RatioN/A
Book Value$3.52
Div Yield0%
Shares O/S30.57M
Ave Daily Vol560,082
Short Int10.18%

Current

Price$2.23
Market Cap$0.13B
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Its products include Omadacycline and Sarecycline. The company was founded in February 2001 and is headquartered in Boston, MA.

Publicly traded companies mentioned herein: Allergan PLC (AGN), Hercules Capital Inc (HTGC), Merck & Co Inc (MRK), Paratek Pharmaceuticals Inc (PRTK), Pfizer Inc (PFE), Zai Lab Ltd (ZLAB)

Highlights

Shares of Paratek Pharmaceuticals (PRTK) have declined over 30% YTD, and recently traded down to the point where the EV was slightly negative. With ~$340MM in cash and equivalents on its balance, and a present market cap that is just ~$10MM higher, the presenter is long the stock. He sees the $11 - $12 range as an attractive entry point given the setup, and noted that PRTK is developing omadacycline, an investigational broad-spectrum antibiotic that the FDA accepted for priority review in April (2018). With multiple upcoming catalysts, including an advisory committee meeting this summer, an October 2018 PDUFA date, and data on omadacycline’s use in treating urinary tract infections (UTIs), shareholders have multiple sources of upside over the next 6 months. Longer-term, there is optionality around M&A.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.